Business Context and Reporting Period
Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc.) filed this Form 8-K regarding events beginning August 3, 2021, with the report signed August 6, 2021. The company completed its merger with Decoy Biosystems, Inc., a preclinical biotechnology company developing a systemically administered anti-cancer and anti-viral immunotherapy.
Following the merger, the company changed its name to Indaptus Therapeutics, Inc., and Decoy’s business became the company’s primary business. Former Decoy stockholders owned approximately 65.6% of the company immediately after closing, while former Intec Israel shareholders owned approximately 34.4%.
Key Financial and Capitalization Information
- Immediately following the merger, 5,405,963 shares of common stock were outstanding, excluding shares issuable upon exercise of outstanding warrants and options.
- Assuming full exercise of the pre-funded warrants sold in the private placement, 8,133,236 shares would be outstanding.
- The filing does not provide clear revenue, profit or loss, operating cash flow, cash balance, liquidity, debt, or margin figures.
- The filing references completion of a private placement but does not provide its proceeds or detailed terms in the supplied text.
- Expected costs associated with winding down the Accordion Pill business include approximately $800,000 of salaries, severance and close-out expenses.
- Termination of the Process Development Agreement with LTS is expected to result in approximately €2.2 million, or approximately $2.6 million, of termination fees and related expenses.
- Termination of the Jerusalem office lease is expected to result in a $600,000 break-up fee.
Material Changes Versus the Prior Comparable Period
- The transaction resulted in a change of control, with former Decoy stockholders becoming the controlling shareholder group.
- The company transitioned from the Intec-related business to Decoy’s preclinical immunotherapy business.
- The board decided to wind down Intec Israel’s Accordion Pill business and began terminating related contracts and selling related assets.
- The company’s common stock began trading on Nasdaq under the ticker INDP at market open on August 4, 2021.
- The company changed its corporate name and amended its certificate of incorporation.
Outlook, Risks, Contingencies and Unusual Items
- The Accordion Pill wind-down was expected to be substantially complete by the end of the third quarter of 2021.
- The company expected to incur an impairment charge related to the wind-down but had not determined an estimate or range as of the filing date. It stated that it would file a subsequent Form 8-K within four business days after determining the charge.
- The company planned to retain an adequate number of employees in Israel during the wind-down, creating ongoing salary and severance obligations.
- The merger and business transition expose investors to the development, regulatory, financing and execution risks typical of a preclinical biotechnology company.
- Unaudited interim financial statements for Decoy through March 31, 2021 were attached, while required pro forma financial information was to be filed no later than 71 calendar days after the Form 8-K filing deadline.
Facts Investors Should Verify
- Final merger consideration, including the impact of converted SAFEs, preferred stock and stock options.
- Private placement proceeds, warrant terms and fully diluted share count.
- Decoy’s March 31, 2021 financial condition and subsequent pro forma financial statements.
- The final impairment charge and total costs of winding down the Accordion Pill business.
- Actual cash runway, financing requirements and development milestones for the immunotherapy pipeline.
- Completion status and final costs of the LTS contract and Jerusalem lease terminations.